Translational and pharmacological principles of hyperthermic intraperitoneal chemotherapy for ovarian cancer

Laura M.C. Vos, S. Lot Aronson, Willemien J. van Driel, Alwin D.R. Huitema, Jules H. Schagen van Leeuwen, Christine A.R. Lok, Gabe S. Sonke

Research output: Contribution to journalReview articlepeer-review

11 Citations (Scopus)


The long-term survival of advanced-stage ovarian cancer patients remains poor, despite extensive cytoreductive surgery, chemotherapy, and the recent addition of poly (ADP-ribose) polymerase inhibitors (PARPi). Hyperthermic intraperitoneal chemotherapy (HIPEC) has shown survival benefit by specifically targeting peritoneal metastases, the primary site of disease recurrence. Different aspects of how HIPEC exerts its effect remain poorly understood. Improved understanding of the effects of hyperthermia on ovarian cancer cells, the synergy of hyperthermia with intraperitoneal chemotherapy, and the pharmacological and pharmacokinetic properties of intraperitoneally administered cisplatin may help identify ways to optimize the efficacy of HIPEC. This review provides an overview of these translational and pharmacological principles of HIPEC and aims to expose knowledge gaps that may direct further research to optimize the HIPEC procedure and ultimately improve survival for women with advanced ovarian cancer.

Original languageEnglish
Pages (from-to)86-102
Number of pages17
JournalBest Practice and Research: Clinical Obstetrics and Gynaecology
Publication statusPublished - Jan 2022


  • Hyperthermia
  • Hyperthermic intraperitoneal chemotherapy
  • Ovarian cancer
  • Pharmacokinetics
  • Pharmacology
  • Translational medical research


Dive into the research topics of 'Translational and pharmacological principles of hyperthermic intraperitoneal chemotherapy for ovarian cancer'. Together they form a unique fingerprint.

Cite this